Overview
RGEN market data
Price History
RGEN price chart
Valuation & Profitability
- P/E (TTM)
- 166.67 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.86 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.02 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $100.99 – $175.77 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $8.6K · P/B 4.38 · P/S 11.22.
Company News
JP Morgan Maintains Overweight on Repligen, Raises Price Target to $175Benzinga · Jul 29, 2026, 6:36 PM
Nasdaq 100 Enters Correction, SanDisk Sinks Over 50% From Peak: Stock Market TodayBenzinga · Jul 28, 2026, 5:21 PM
12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga · Jul 28, 2026, 5:06 PM
Repligen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance.Benzinga · Jul 28, 2026, 2:18 PM
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On TuesdayBenzinga · Jul 28, 2026, 2:05 PM
8-K filing — REPLIGEN CORP (RGEN)SEC EDGAR · Jul 28, 2026, 11:13 AM
Repligen Q2 Adj. EPS $0.54 Beats $0.45 Estimate, Sales $204.128M Beat $201.483M EstimateBenzinga · Jul 28, 2026, 11:02 AM
Repligen Raises FY2026 Adj EPS Guidance from $1.97-$2.05 to $2.03-$2.09 vs $2.00 Est; Raises FY2026 Sales Guidance from $803.000M-$833.000M to $813.000M-$835.000M vs $822.537M EstBenzinga · Jul 28, 2026, 11:01 AM
Repligen Strengthens Cell Therapy Portfolio With BioLife AcquisitionBenzinga · Jul 22, 2026, 1:42 PM
BioLife Solutions To Be Acquired By Repligen For $31 Per Share In Cash And RGEN Stock At EV Of ~$1.5BBenzinga · Jul 22, 2026, 10:03 AM